This discussion is meant to be informative for pharmacists who are less familiar with immunotherapy-related adverse events, as well as to offer insight into decision making in challenging situations related to managing irAEs.
Jordan McPherson, Pharm.D., M.S., BCOP is Oncology Clinical Pharmacist in the ambulatory solid tumor clinics at the Huntsman Cancer Institute, an NCI designated cancer hospital, at the University of Utah Health and Adjunct Assistant Professor at the University of Utah College of Pharmacy in Salt Lake City, Utah. Dr. McPherson specializes in the treatment of skin cancer using immunotherapy and other targeted therapies. He serves as a Panelist on the NCCN Guidelines for Management of Immune Checkpoint Inhibitor-Related Toxicities, and is Past President of the Utah Society of Health-System Pharmacists. Dr. McPherson’s research efforts are well published in peer reviewed journals, including the Journal of Clinical Oncology, Journal for ImmunoTherapy of Cancer, and Pharmacotherapy.
Tonya Smith, Pharm.D., BCPS, is Clinical Pharmacy Specialist in Internal Medicine at Emory University Hospital Midtown in Atlanta, Georgia. Dr. Smith received her Pharm.D. degree from the Medical University of South Carolina in Charleston, South Carolina. She completed her PGY1 Pharmacy Practice Residency and PGY2 Internal Medicine Pharmacy Residency at University of Utah Health in Salt Lake City, Utah. Prior to Emory, Dr. Smith practiced on the inpatient medical oncology service and the Supportive Oncology & Survivorship Clinic at the Huntsman Cancer Institute in Salt Lake City, Utah.
This podcast is provided by ASHP and supported by an independent medical education grant from Merck, Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.